Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance

The tumor microenvironment (TME) plays a pivotal role in cancer development and progression. In this line, revealing the precise mechanisms of the TME and associated signaling pathways of tumor resistance could pave the road for cancer prevention and efficient treatment. The use of nanomedicine could be a step forward in overcoming the barriers in tumor-targeted therapy. Novel delivery systems benefit from enhanced permeability and retention effect, decreasing tumor resistance, reducing tumor hypoxia, and targeting tumor-associated factors, including immune cells, endothelial cells, and fibroblasts. Emerging evidence also indicates the engagement of multiple dysregulated mediators in the TME, such as matrix metalloproteinase, vascular endothelial growth factor, cytokines/chemokines, Wnt/β-catenin, Notch, Hedgehog, and related inflammatory and apoptotic pathways. Hence, investigating novel multitargeted agents using a novel delivery system could be a promising strategy for regulating TME and drug resistance. In recent years, small molecules from natural sources have shown favorable anticancer responses by targeting TME components. Nanoformulations of natural compounds are promising therapeutic agents in simultaneously targeting multiple dysregulated factors and mediators of TME, reducing tumor resistance mechanisms, overcoming interstitial fluid pressure and pericyte coverage, and involvement of basement membrane. The novel nanoformulations employ a vascular normalization strategy, stromal/matrix normalization, and stress alleviation mechanisms to exert higher efficacy and lower side effects. Accordingly, the nanoformulations of anticancer monoclonal antibodies and conventional chemotherapeutic agents also improved their efficacy and lessened the pharmacokinetic limitations. Additionally, the coadministration of nanoformulations of natural compounds along with conventional chemotherapeutic agents, monoclonal antibodies, and nanomedicine-based radiotherapy exhibits encouraging results. This critical review evaluates the current body of knowledge in targeting TME components by nanoformulation-based delivery systems of natural small molecules, monoclonal antibodies, conventional chemotherapeutic agents, and combination therapies in both preclinical and clinical settings. Current challenges, pitfalls, limitations, and future perspectives are also discussed.

Chemopreventive Potential of Dietary Nanonutraceuticals for Prostate Cancer: An Extensive Review

There are more than two hundred fifty different types of cancers, that are diagnosed around the world. Prostate cancer is one of the suspicious type of cancer spreading very fast around the world, it is reported that in 2018, 29430 patients died of prostate cancer in the United State of America (USA), and hence it is expected that one out of nine men diagnosed with this severe disease during their lives. Medical science has identified cancer at several stages and indicated genes mutations involved in the cancer cell progressions. Genetic implications have been studied extensively in cancer cell growth. So most efficacious drug for prostate cancer is highly required just like other severe diseases for men. So nutraceutical companies are playing major role to manage cancer disease by the recommendation of best natural products around the world, most of these natural products are isolated from plant and mushrooms because they contain several chemoprotective agents, which could reduce the chances of development of cancer and protect the cells for further progression. Some nutraceutical supplements might activate the cytotoxic chemotherapeutic effects by the mechanism of cell cycle arrest, cell differentiation procedures and changes in the redox states, but in other, it also elevate the levels of effectiveness of chemotherapeutic mechanism and in results, cancer cell becomes less reactive to chemotherapy. In this review, we have highlighted the prostate cancer and importance of nutraceuticals for the control and management of prostate cancer, and the significance of nutraceuticals to cancer patients during chemotherapy.

A genomic characterization of the influence of silver nanoparticles on bone differentiation in MC3T3-E1 cells

Silver nanoparticles (AgNPs) have been widely used in a variety of biomedical applications. Previous studies demonstrated that AgNPs significantly enhanced bone cell mineralization and differentiation in MC3T3-1 cells, a model in vitro system, when compared to several other NPs. This increased bone deposition was evaluated by phenotypic measurements and assessment of the expression of miRNAs associated with regulation of bone morphogenic proteins. In the present study, we used RNA-seq technology, a more direct measurement of gene expression, to investigate further the mechanisms of bone differentiation induced by AgNP treatment. Key factors associated with the osteoclast pathway were significantly increased in response to AgNP exposure including Bmp4, Bmp6 and Fosl1. In addition, genes of metabolism and toxicity pathways were significantly regulated as well. Although this study suggests the potential for AgNPs to influence bone morphogenesis in injury or disease applications, further investigation into the efficacy and safety of AgNPs in bone regeneration is warranted.

Rational Design of GO-Modified Fe3O4/SiO2 Nanoparticles with Combined Rhenium-188 and Gambogic Acid for Magnetic Target Therapy

Peanutlike magnetic-fluorescent Fe₃O₄/SiO₂ nanoparticles, with an effective dynamic diameter of 180 nm, were synthesized via EuO⁺ doping and coupling of two Fe₃O₄ cores and reassembling through the solvothermal process. Spherical pure Fe₃O₄/SiO₂ nanoparticles with an effective dynamic diameter of 230 nm were also prepared for comparison. We designed graphene oxide (GO)-modified core-shell Fe₃O₄/SiO₂ nanoparticles as a nanocarrier for loading gambogic acid (GA) following labeling with radioisotope rhenium-188. We also performed GA loading and releasing on GA-loaded magnetic nanoparticles, in vivo biodistribution, and magnetic drug targeting therapy experiments. Results indicated that the GA-loaded magnetic nanoparticles demonstrate a clear pH-dependent drug release behavior, having a higher release rate in acidic environments. The in vivo biodistribution of the magnetic nanoparticles has morphologic dependency, and the peanutlike nanoparticles (PN-Fe₃O₄) tend to accumulate more in the spleen, lung, and liver than in the spherical nanoparticles (S-Fe₃O₄). The targeted therapy showed a higher efficacy of PN-Fe₃O₄ in inhibiting tumor cell growth than the nontargeted therapy. The polyethyleneimine (PEI) grafting of PN-Fe₃O₄ with amide bond was also designed to find an effective active targeting antitumor agent considering the fact that the PEI-GO conjugate has a higher GA load efficiency and the convergence effect.

Functional nanoparticle-decorated graphene oxide sheets as stabilizers for Pickering high internal phase emulsions and graphene oxide based foam monoliths

A facile and versatile approach was developed for the preparation of graphene oxide sheet-based Pickering high internal phase emulsions by nanoparticle decoration.